Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sirolimus ophthalmic - Santen Pharmaceutical

Drug Profile

Sirolimus ophthalmic - Santen Pharmaceutical

Alternative Names: DE-109; MS-R001; Opsiria; Perceiva

Latest Information Update: 11 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MacuSight
  • Developer Johns Hopkins University; MacuSight; Midwest Eye Institute; Santen Pharmaceutical
  • Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveitis
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Uveitis
  • Phase III Wet age-related macular degeneration
  • Discontinued Diabetic macular oedema; Dry eyes

Most Recent Events

  • 19 Nov 2018 Santen initiates the phase III LUMINA trial for Uveitis in USA (Intravitreous) (NCT03711929)
  • 19 Oct 2018 Santen plans the phase III LUMINA trial for Uveitis in the US in November 2018 (Intravitreous) (NCT03711929)
  • 21 Dec 2017 Santen Pharmaceutical receives complete response letter from the FDA for intravitreal sirolimus in Uveitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top